newsfilter
← Latest News
Business Wire·

Alzamend Neuro to Present at the Sequire Investor Summit

Company to report on progress with clinical trials to be initiated in 2025 and expected milestones Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company, focused on developing